484 related articles for article (PubMed ID: 34445385)
41. Avelumab: A Review in Metastatic Merkel Cell Carcinoma.
Shirley M
Target Oncol; 2018 Jun; 13(3):409-416. PubMed ID: 29799096
[TBL] [Abstract][Full Text] [Related]
42. Avelumab: search for combinations of immune checkpoint inhibition with chemotherapy.
Hamilton G
Expert Opin Biol Ther; 2021 Mar; 21(3):311-322. PubMed ID: 32954871
[TBL] [Abstract][Full Text] [Related]
43. Global PD-L1 Signals and Tumor-Infiltrating Lymphocytes: Markers of Immunogenicity in Different Subsets of Merkel Cell Carcinoma and Potential Therapeutic Implications.
Walsh NM; Castonguay MC; Carter MD; Pasternak S; Ly TY; Doucette S; Hanly JG; Saggini A; Cerroni L
Am J Dermatopathol; 2019 Nov; 41(11):819-825. PubMed ID: 31634167
[TBL] [Abstract][Full Text] [Related]
44. Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma.
Church C; Pulliam T; Longino N; Park SY; Smythe KS; Makarov V; Riaz N; Jing L; Amezquita R; Campbell JS; Gottardo R; Pierce RH; Choi J; Chan TA; Koelle DM; Nghiem P
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36252564
[TBL] [Abstract][Full Text] [Related]
45. Complete spontaneous regression of primary Merkel cell carcinoma with tumoural infiltration: a systematic review.
Ah-Thiane L; Samimi M; Kervarrec T; Khammari A; Dréno B
Eur J Dermatol; 2021 Jun; 31(3):381-391. PubMed ID: 34080974
[TBL] [Abstract][Full Text] [Related]
46. PD-1 and PD-L1 in neoplastic cells and the tumor microenvironment of Merkel cell carcinoma.
Mitteldorf C; Berisha A; Tronnier M; Pfaltz MC; Kempf W
J Cutan Pathol; 2017 Sep; 44(9):740-746. PubMed ID: 28569410
[TBL] [Abstract][Full Text] [Related]
47. The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy.
Knepper TC; Montesion M; Russell JS; Sokol ES; Frampton GM; Miller VA; Albacker LA; McLeod HL; Eroglu Z; Khushalani NI; Sondak VK; Messina JL; Schell MJ; DeCaprio JA; Tsai KY; Brohl AS
Clin Cancer Res; 2019 Oct; 25(19):5961-5971. PubMed ID: 31399473
[TBL] [Abstract][Full Text] [Related]
48. PD-1 blockade: a therapeutic option for treatment of metastatic Merkel cell carcinoma.
Winkler JK; Bender C; Kratochwil C; Enk A; Hassel JC
Br J Dermatol; 2017 Jan; 176(1):216-219. PubMed ID: 27038231
[TBL] [Abstract][Full Text] [Related]
49. An Updated Review of the Biomarkers of Response to Immune Checkpoint Inhibitors in Merkel Cell Carcinoma: Merkel Cell Carcinoma and Immunotherapy.
Fojnica A; Ljuca K; Akhtar S; Gatalica Z; Vranic S
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894451
[TBL] [Abstract][Full Text] [Related]
50. Immune checkpoint inhibitors to treat cutaneous malignancies.
Barrios DM; Do MH; Phillips GS; Postow MA; Akaike T; Nghiem P; Lacouture ME
J Am Acad Dermatol; 2020 Nov; 83(5):1239-1253. PubMed ID: 32461079
[TBL] [Abstract][Full Text] [Related]
51. Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma.
Schadendorf D; Nghiem P; Bhatia S; Hauschild A; Saiag P; Mahnke L; Hariharan S; Kaufman HL
Oncoimmunology; 2017; 6(10):e1338237. PubMed ID: 29123950
[TBL] [Abstract][Full Text] [Related]
52. Real-world clinical outcomes with first-line avelumab in locally advanced/metastatic Merkel cell carcinoma in the USA: SPEAR-Merkel.
Cowey CL; Liu FX; Kim R; Boyd M; Fulcher N; Krulewicz S; Kasturi V; Bhanegaonkar A
Future Oncol; 2021 Jun; 17(18):2339-2350. PubMed ID: 33709776
[TBL] [Abstract][Full Text] [Related]
53. Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients.
Leiter U; Loquai C; Reinhardt L; Rafei-Shamsabadi D; Gutzmer R; Kaehler K; Heinzerling L; Hassel JC; Glutsch V; Sirokay J; Schlecht N; Rübben A; Gambichler T; Schatton K; Pfoehler C; Franklin C; Terheyden P; Haferkamp S; Mohr P; Bischof L; Livingstone E; Zimmer L; Weichenthal M; Schadendorf D; Meiwes A; Keim U; Garbe C; Becker JC; Ugurel S
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33093156
[TBL] [Abstract][Full Text] [Related]
54. Merkel cell polyomavirus-specific and CD39
Ryu H; Bi TM; Pulliam TH; Sarkar K; Church CD; Kumar N; Mayer-Blackwell K; Jani S; Ramchurren N; Hansen UK; Hadrup SR; Fling SP; Koelle DM; Nghiem P; Newell EW
Cell Rep Med; 2024 Feb; 5(2):101390. PubMed ID: 38340724
[TBL] [Abstract][Full Text] [Related]
55. Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions.
Gallo M; Guarnotta V; De Cicco F; Rubino M; Faggiano A; Colao A;
J Cancer Res Clin Oncol; 2019 Feb; 145(2):429-443. PubMed ID: 30617553
[TBL] [Abstract][Full Text] [Related]
56. Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models.
Waaler J; Mygland L; Tveita A; Strand MF; Solberg NT; Olsen PA; Aizenshtadt A; Fauskanger M; Lund K; Brinch SA; Lycke M; Dybing E; Nygaard V; Bøe SL; Heintz KM; Hovig E; Hammarström C; Corthay A; Krauss S
Commun Biol; 2020 Apr; 3(1):196. PubMed ID: 32332858
[TBL] [Abstract][Full Text] [Related]
57. Updates on Merkel Cell Carcinoma.
Emge DA; Cardones AR
Dermatol Clin; 2019 Oct; 37(4):489-503. PubMed ID: 31466589
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial.
D'Angelo SP; Russell J; Lebbé C; Chmielowski B; Gambichler T; Grob JJ; Kiecker F; Rabinowits G; Terheyden P; Zwiener I; Bajars M; Hennessy M; Kaufman HL
JAMA Oncol; 2018 Sep; 4(9):e180077. PubMed ID: 29566106
[TBL] [Abstract][Full Text] [Related]
59. Human CD4
Longino NV; Yang J; Iyer JG; Ibrani D; Chow IT; Laing KJ; Campbell VL; Paulson KG; Kulikauskas RM; Church CD; James EA; Nghiem P; Kwok WW; Koelle DM
Cancer Immunol Res; 2019 Oct; 7(10):1727-1739. PubMed ID: 31405946
[TBL] [Abstract][Full Text] [Related]
60. The HDAC Inhibitor Domatinostat Promotes Cell-Cycle Arrest, Induces Apoptosis, and Increases Immunogenicity of Merkel Cell Carcinoma Cells.
Song L; Bretz AC; Gravemeyer J; Spassova I; Muminova S; Gambichler T; Sriram A; Ferrone S; Becker JC
J Invest Dermatol; 2021 Apr; 141(4):903-912.e4. PubMed ID: 33002502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]